.png)
The Non-coding RNA Journal Webinar Series | A First-In-Class microRNA-Targeted Therapeutic Against Metastatic Cancers of Diverse Primary Disease Origins
the chair
The Non-coding RNA Journal Webinar Series
A First-In-Class microRNA-Targeted Therapeutic Against Metastatic Cancers of Diverse Primary Disease Origins
The Non-coding RNA journal webinar is open to those who enjoy carrying out any type of research on the topic of non-coding transcripts or are passionate about learning about this exciting and competitive research area. The webinar speakers will present new findings from basic to translational research. Any interesting ideas for topics and speakers are welcomed!
Date: 19 September 2023
Time: 4:00 pm CEST | 9:00 am CDT | 10:00 am EDT | 10:00 pm CST Asia
Webinar ID: 891 4103 6850
Webinar Secretariat: ncrna.webinar@mdpi.com
Meet Our Chair
Department of Translational Molecular Pathogenesis, Center for RNA Interference and Non-coding RNAs, University of Texas MD Anderson Cancer Center, Houston, TX, USA;Prof. Dr.George A. Calin received both his M.D. and Ph.D. degrees at Carol Davila University of Medicine in Bucharest, Romania. After working in cytogenetics as an undergraduate student with Dragos Stefanescu in Bucharest, Calin completed cancer genomics training in Massimo Negrini’s laboratory at the University of Ferrara, Italy, and in 2000, he became a postdoctoral fellow in Carlo Croce’s laboratory at Kimmel Cancer Center in Philadelphia, Pennsylvania. In June 2007, Calin joined MD Anderson as an associate professor in the Experimental Therapeutics department and was promoted to Professor with tenure in 2013. He explores new RNA therapeutic options for cancer patients and studies the roles of microRNAs and other non-coding RNAs in cancer initiation and progression, as well as the mechanisms of cancer predisposition.
Meet Our Speaker
Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA;Transcode Therapeutics, Inc., Boston, MA, USA;Dr. Medarova is Chief Technology Officer at TransCode Therapeutics, Inc. Dr. Medarova carried out seminal work in the field of RNA oncology. Together with her colleagues at Harvard Medical School, she advanced research validating microRNAs as therapeutic targets and diagnostic biomarkers in cancer. Her work generated substantial interest in the research community since it illustrated the value of nanotechnology for delivering RNA therapy for oncology applications and described approaches for the noninvasive monitoring of RNA delivery. Since then, Dr. Medarova has emerged as one of the leaders in the field of non-coding RNA delivery to cancer. She has developed a robust NIH-funded program and authored multiple high-impact publications on the topic of RNA delivery, nanotechnology, and the biology of cancer metastasis. Dr. Medarova obtained a B.A. in pre-medicine from the University of Southern Maine and a Ph.D. in Genetics from the University of New Hampshire.
In this section, you will find the recordings of this webinar to watch, re-watch and share with your colleagues!